[8-K] Adaptimmune Therapeutics plc American Reports Material Event
Adaptimmune Therapeutics plc announced second-quarter financial results for the period ended June 30, 2025 and provided a corporate update. The Form 8-K furnishes the companys press release as Exhibit 99.1 and states that the furnished information is not deemed "filed" for purposes of Section 18 and is not incorporated by reference except by specific reference.
The filing does not include the financial figures or operational details; the full press release attached as Exhibit 99.1 contains the detailed results and corporate update.
Adaptimmune Therapeutics plc ha annunciato i risultati finanziari del secondo trimestre per il periodo chiuso il 30 giugno 2025 e ha fornito un aggiornamento aziendale. Il Modulo 8-K fornisce il comunicato stampa della societ脿 come Exhibit 99.1 e precisa che le informazioni fornite non sono considerate 'depositate' ai fini della Sezione 18 e non sono incorporate per riferimento, salvo espressa indicazione.
La presentazione non include i dati finanziari n茅 i dettagli operativi; il comunicato stampa completo allegato come Exhibit 99.1 contiene i risultati dettagliati e l'aggiornamento aziendale.
Adaptimmune Therapeutics plc anunci贸 los resultados financieros del segundo trimestre correspondientes al periodo terminado el 30 de junio de 2025 y ofreci贸 una actualizaci贸n corporativa. El Formulario 8-K incorpora el comunicado de prensa de la compa帽铆a como Exhibit 99.1 y se帽ala que la informaci贸n facilitada no se considera 'presentada' a los efectos de la Secci贸n 18 y no se incorpora por referencia, salvo que se indique expresamente.
La presentaci贸n no incluye las cifras financieras ni los detalles operativos; el comunicado de prensa completo adjunto como Exhibit 99.1 contiene los resultados detallados y la actualizaci贸n corporativa.
Adaptimmune Therapeutics plc電� 2025雲� 6鞗� 30鞚� 膦呺霅� 旮瓣皠鞐� 雽�頃� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃橁碃 旮办梾 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. Form 8-K電� 須岇偓鞚� 氤措弰鞛愲毳� Exhibit 99.1搿� 觳秬頃橂┌, 鞝滉车霅� 鞝曤炒電� 靹轨厴 18鞚� 氇╈爜靸� '鞝滌稖霅�(filed)' 瓴冹溂搿� 臧勳＜霅橃 鞎婌溂氅� 韸轨爼頃� 彀胳“搿� 氇呾嫓鞝侅溂搿� 韽暔霅橂姅 瓴届毎毳� 鞝滌櫢頃橁碃電� 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�.
鞚措矆 鞝滌稖鞐愲姅 鞛 靾橃箻雮� 鞖挫榿 靹鸽秬靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞝勳泊 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅� 靸侅劯頃� 瓴瓣臣鞕� 旮办梾 鞐呺嵃鞚错姼毳� 雼搓碃 鞛堨姷雼堧嫟.
Adaptimmune Therapeutics plc a annonc茅 les r茅sultats financiers du deuxi猫me trimestre pour la p茅riode close le 30 juin 2025 et a fourni une mise 脿 jour d'entreprise. Le formulaire 8-K fournit le communiqu茅 de presse de la soci茅t茅 en tant que Exhibit 99.1 et indique que les informations fournies ne sont pas consid茅r茅es comme 'd茅pos茅es' aux fins de la Section 18 et ne sont pas incorpor茅es par renvoi, sauf mention expresse.
Le d茅p么t n'inclut pas les chiffres financiers ni les d茅tails op茅rationnels ; le communiqu茅 de presse complet annex茅 en tant que Exhibit 99.1 contient les r茅sultats d茅taill茅s et la mise 脿 jour d'entreprise.
Adaptimmune Therapeutics plc gab die Finanzergebnisse des zweiten Quartals f眉r den Zeitraum zum 30. Juni 2025 bekannt und ver枚ffentlichte ein Unternehmensupdate. Das Formular 8-K stellt die Pressemitteilung des Unternehmens als Exhibit 99.1 zur Verf眉gung und erkl盲rt, dass die bereitgestellten Informationen f眉r Zwecke von Section 18 nicht als 'eingereicht' ('filed') gelten und nicht durch Verweis eingegliedert werden, es sei denn, dies geschieht durch ausdr眉ckliche Bezugnahme.
Die Einreichung enth盲lt keine Finanzzahlen oder operativen Details; die vollst盲ndige Pressemitteilung als Exhibit 99.1 enth盲lt die ausf眉hrlichen Ergebnisse und das Unternehmensupdate.
- Company announced Q2 results for the period ended June 30, 2025 and provided a corporate update as stated in the filing.
- Press release furnished as Exhibit 99.1, making the corporate update and results available in a labeled exhibit.
- Filing does not include financial figures or operational detail in the body of the Form 8-K, so metrics are not available here.
- Information is "furnished" not "filed", which limits automatic incorporation by reference into other SEC filings.
Insights
TL;DR: Routine earnings disclosure furnished; no financial data included in the filing itself, limiting immediate assessment of performance.
The Form 8-K notifies investors that Adaptimmune announced second-quarter results for the period ended June 30, 2025 and furnished a press release as Exhibit 99.1. The company explicitly states the material is "furnished" and not "filed," which limits automatic incorporation into other SEC filings. Because this filing does not contain revenue, profit, cash flow, guidance or other quantitative metrics, the filing alone does not allow evaluation of operational or financial trends; the press release (Exhibit 99.1) must be reviewed for substantive metrics.
TL;DR: Procedural 8-K furnishing a press release and clarifying legal status of the disclosure; appears to be standard corporate reporting practice.
The company furnished a press release and included a customary statement that furnished information is not "filed" under Section 18 and is not incorporated by reference except by specific reference. This language and the exhibit listing (including Exhibit 99.1 and the Inline XBRL cover page) are consistent with routine disclosure practices for earnings announcements and corporate updates. No governance issues, leadership changes, or material transactions are disclosed in this filing.
Adaptimmune Therapeutics plc ha annunciato i risultati finanziari del secondo trimestre per il periodo chiuso il 30 giugno 2025 e ha fornito un aggiornamento aziendale. Il Modulo 8-K fornisce il comunicato stampa della societ脿 come Exhibit 99.1 e precisa che le informazioni fornite non sono considerate 'depositate' ai fini della Sezione 18 e non sono incorporate per riferimento, salvo espressa indicazione.
La presentazione non include i dati finanziari n茅 i dettagli operativi; il comunicato stampa completo allegato come Exhibit 99.1 contiene i risultati dettagliati e l'aggiornamento aziendale.
Adaptimmune Therapeutics plc anunci贸 los resultados financieros del segundo trimestre correspondientes al periodo terminado el 30 de junio de 2025 y ofreci贸 una actualizaci贸n corporativa. El Formulario 8-K incorpora el comunicado de prensa de la compa帽铆a como Exhibit 99.1 y se帽ala que la informaci贸n facilitada no se considera 'presentada' a los efectos de la Secci贸n 18 y no se incorpora por referencia, salvo que se indique expresamente.
La presentaci贸n no incluye las cifras financieras ni los detalles operativos; el comunicado de prensa completo adjunto como Exhibit 99.1 contiene los resultados detallados y la actualizaci贸n corporativa.
Adaptimmune Therapeutics plc電� 2025雲� 6鞗� 30鞚� 膦呺霅� 旮瓣皠鞐� 雽�頃� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃橁碃 旮办梾 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. Form 8-K電� 須岇偓鞚� 氤措弰鞛愲毳� Exhibit 99.1搿� 觳秬頃橂┌, 鞝滉车霅� 鞝曤炒電� 靹轨厴 18鞚� 氇╈爜靸� '鞝滌稖霅�(filed)' 瓴冹溂搿� 臧勳＜霅橃 鞎婌溂氅� 韸轨爼頃� 彀胳“搿� 氇呾嫓鞝侅溂搿� 韽暔霅橂姅 瓴届毎毳� 鞝滌櫢頃橁碃電� 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�.
鞚措矆 鞝滌稖鞐愲姅 鞛 靾橃箻雮� 鞖挫榿 靹鸽秬靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞝勳泊 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅� 靸侅劯頃� 瓴瓣臣鞕� 旮办梾 鞐呺嵃鞚错姼毳� 雼搓碃 鞛堨姷雼堧嫟.
Adaptimmune Therapeutics plc a annonc茅 les r茅sultats financiers du deuxi猫me trimestre pour la p茅riode close le 30 juin 2025 et a fourni une mise 脿 jour d'entreprise. Le formulaire 8-K fournit le communiqu茅 de presse de la soci茅t茅 en tant que Exhibit 99.1 et indique que les informations fournies ne sont pas consid茅r茅es comme 'd茅pos茅es' aux fins de la Section 18 et ne sont pas incorpor茅es par renvoi, sauf mention expresse.
Le d茅p么t n'inclut pas les chiffres financiers ni les d茅tails op茅rationnels ; le communiqu茅 de presse complet annex茅 en tant que Exhibit 99.1 contient les r茅sultats d茅taill茅s et la mise 脿 jour d'entreprise.
Adaptimmune Therapeutics plc gab die Finanzergebnisse des zweiten Quartals f眉r den Zeitraum zum 30. Juni 2025 bekannt und ver枚ffentlichte ein Unternehmensupdate. Das Formular 8-K stellt die Pressemitteilung des Unternehmens als Exhibit 99.1 zur Verf眉gung und erkl盲rt, dass die bereitgestellten Informationen f眉r Zwecke von Section 18 nicht als 'eingereicht' ('filed') gelten und nicht durch Verweis eingegliedert werden, es sei denn, dies geschieht durch ausdr眉ckliche Bezugnahme.
Die Einreichung enth盲lt keine Finanzzahlen oder operativen Details; die vollst盲ndige Pressemitteilung als Exhibit 99.1 enth盲lt die ausf眉hrlichen Ergebnisse und das Unternehmensupdate.
FAQ
What did Adaptimmune (ADAP) disclose in this Form 8-K?
Does the Form 8-K include Q2 2025 financial figures for ADAP?
Where can I find the full press release referenced in the 8-K?
Is the furnished press release considered "filed" or incorporated by reference?
What is Adaptimmunes ticker symbol and listing?
